drugset / Trial / NCT05979415
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
Phase 2
Terminated
8 enrolled
Alexza Pharmaceuticals, Inc.
DSG, Inc · collabISS, Inc. · collabPeachtree BioResearch Solutions Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
Timeline
- Start
- 2023-09-27
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apomorphine | Unknown | 1 mg | — |
| Comparator | Apomorphine | Unknown | 2 mg | — |
| Comparator | Apomorphine | Unknown | 3 mg | — |
| Comparator | Apomorphine | Unknown | 4 mg | — |